Swirling flow vascular stent for the treatment of femoropopliteal lesions
Leaving the right thing behind?
References
1 Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study. Lancet Glob Health. 2020;8(5):e721–9.
2 The adjuvant benefit of angioplasty in patients with mild to moderate intermittent claudication (MIMIC) managed by supervised exercise, smoking cessation advice and best medical therapy: results from two randomised trials for stenotic femoropopliteal and aortoiliac arterial disease. Eur J Vasc Endovasc Surg. 2008;36(6):680–8.
3 Editor’s Choice – Comorbidity patterns among patients with peripheral arterial occlusive disease in germany: a trend analysis of health insurance claims data. Eur J Vasc Endovasc Surg. 2020;59(1):59–66.
4 . Ten year mortality in different peripheral arterial disease stages: a population based observational study on outcome. Eur J Vasc Endovasc Surg. 2018;55(4):529–36.
5 ESVM guideline on peripheral arterial disease. VASA. 2019;48(Suppl 102):1–79.
6 Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354(18):1879–88.
7 Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133(15):1472–83. Discussion 1483.
8 Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg. 2011;54(4):1042–50.
9 . The role of atherectomy in peripheral artery disease: current evidence and future perspectives. VER J [Internet]. 2018. Available from: https://www.verjournal.com/articles/atherectomy-peripheral-artery-disease
10 Directional atherectomy before paclitaxel coated balloon angioplasty in complex femoropopliteal disease: The VIVA REALITY study. Catheter Cardiovasc Interv. 2021;98(3):549–58.
11 Safety and effectiveness of Phoenix atherectomy for endovascular treatment in calcified common femoral artery lesions. VASA. 2021;50(5):378–86.
12 Safety, effectiveness and mid-term follow-up in 136 consecutive patients with moderate to severely calcified lesions undergoing phoenix atherectomy. Heart Vessels. 2021;36(3):366–75.
13 . BioMimics 3D vascular stent system for femoropopliteal interventions. VASA. 2022;51(1):5–12.
14 . Swirling flow and wall shear: Evaluating the BioMimics 3D helical centerline stent for the femoropopliteal segment. Int J Vasc Med. 2018;2018:e9795174.
15 Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115(21):2745–9.
16 Optimized drug-coated balloon angioplasty of the superficial femoral and proximal popliteal arteries using the Tack Endovascular System: TOBA III 12-month results. J Vasc Surg. 2020;72(5):1636–47.